Staging
Initial disease staging in newly diagnosed NSCLC can correctly differentiate patients with potentially curable disease from those indicated for palliative therapy. 18 F-FDG PET/ CT has greater staging accuracy than either of the modalities alone because of the improved detection of additional lymph node involvement or distant metastasis [13, 14] .
T staging
Primary lung tumor extent is mostly evaluated using thoracic CT, which, in cases of superior sulcus extension, thoracic wall invasion, or heart or large vessel involvement, is supplemented by magnetic resonance imaging (MRI). The major contribution of 18 F-FDG PET/CT is accurate tumor delineation from surrounding post-obstructive atelectasis ( Fig. 1) , which is important for therapy planning; 18 F-FDG PET/CT can also be useful for detecting chest wall invasion [15] .
Locoregional lymph node staging (N staging)
The most commonly used technique for N staging of patients with lung cancer is CT, due to its easy accessibility, relatively low cost, and noninvasiveness. Mediastinal and hilar lymph nodes with a short axis of >10 mm are classified as enlarged. However, lymph node size alone has poor specificity for detecting metastatic involvement because enlargement also occurs under benign inflammatory conditions. Moreover, small-sized nodes might contain tumoral deposits [16] . A critical advantage of 18 F-FDG PET/CT over CT is the detection of neoplastic mediastinal adenopathies <1 cm in size (Fig. 2) ; the superiority of 18 F-FDG PET [17] and PET/CT [18, 19] over CT for mediastinal staging is well established. A meta-analysis of 39 studies showed that the median sensitivity and specificity of CT were 61 and 79 %, respectively, whereas those for 18 F-FDG PET were 85 and 90 % [17] . Furthermore, in a meta-analysis including 20 studies involving 3028 patients with NSCLC, 18 F-FDG PET/CT had a pooled sensitivity of 0.72 (95 % CI, 0.68-0.75) and a specificity of 0.90 (95 % CI, 0.88-0.91) [18] . With respect to nodal size, the sensitivity of 18 F-FDG PET/CT in detecting malignant involvement was 32.4 % in nodes <10 mm and 85.3 % in nodes ≥10 mm [19] .
False-negative results due to micrometastasis occur because of the limited spatial resolution of PET, whereas false-positive results were reported in the setting of endemic granulomatous disease. Evidence suggests that 1 3 18 F-FDG PET findings should not replace histological confirmation. A recent multicenter study indicated that 18 F-FDG PET/CT had high NPV (91 %) and specificity (83 %) but a low positive predictive value (PPV) (29 %) [20] . Similar findings were confirmed in a prospective trial where the mediastinal staging of 149 patients by 18 F-FDG PET/CT was confirmed histopathologically; overall sensitivity, specificity, PPV, and NPV were 70, 94, 64, and 95 %, respectively [21] . The low PPV indicated that invasive mediastinal sampling should be conducted when lymph node involvement is suspected and when making curative surgical decisions because false positivity could be a confounding factor, especially in those with granulomatous diseases [22] . In contrast, the high NPV of 18 F-FDG PET/CT suggested that invasive sampling of mediastinal lymph nodes could be safely omitted. False-negative findings may be seen in cases of low tumoral burden in metastatic lymph nodes ("minimal N2"), where a reasonable prognosis after surgical resection is expected [23] . However, in the presence of a centrally located tumor or hilar lymphadenopathy, mediastinoscopy should be conducted because limitations in spatial resolution combined with highly active hilar lymph nodes or tumoral lesions might mask the metabolic activity of nearby lymph nodes.
In summary, 18 F-FDG PET/CT is more accurate for N staging than CT; however, the spatial resolution of PET is not sufficient to detect early lymph node involvement and micrometastases, and 18 F-FDG PET/CT cannot replace histological staging.
Extrathoracic staging (M staging)
Identification of distant metastases has major implications for management and prognosis. Approximately 18-36 % of patients with newly diagnosed NSCLC have distant metastases at presentation [24] . The adrenal glands, bones, liver, and brain are the most common metastatic sites.
Whole-body 18 F-FDG PET/CT is more accurate than conventional imaging for detection of metastatic foci (Fig. 3) [13, 14] . A meta-analysis involving 6 studies with 659 patients [25] revealed that the pooled sensitivity and specificity of 18 F-FDG PET/CT for detecting distant metastasis from NSCLC were 0.87 (95 % CI, 0.55-0.98) and 0.96 (95 % CI, 0.93-0.98), respectively.
18 F-FDG PET/CT has high sensitivity (97 %) and specificity (86 %) for metastatic adrenal disease in NSCLC [26] , which eliminates the need for invasive sampling [27] . However, the partial volume effect must be considered when evaluating small lesions (<1 cm). False positives have been reported; therefore, histopathological confirmation is warranted when treatment decisions are based on an isolated adrenal gland finding.
In patients with lung cancer, whole-body 18 F-FDG PET/ CT for detecting bone metastases showed sensitivity and specificity that were superior to bone scintigraphy [28, 29] . A systematic review that included 6 articles (1746 patients in total) demonstrated that the pooled sensitivity and specificity of 18 F-FDG PET/CT and PET were 0.93 (95 % CI, 0.88-0.96) and 0.95 (95 % CI, 0.91-0.98), respectively, whereas those for bone scintigraphy were 0.87 (95 % CI, 0.79-0.93) and 0.82 (95 % CI, 0.62-0.92), respectively [29] . 18 F-FDG PET/CT can be used as a reliable and noninvasive method for the detection of pleural dissemination (Fig. 4) , but the tiny lesion could not even be detected by 18 F-FDG PET/CT (Fig. 5) . Erasmus et al. [30] reported that the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of pretreatment 18 F-FDG PET/CT for detecting pleural metastases in High glucose uptake by gray matter and small lesion size limit the diagnostic power of 18 F-FDG PET, so MRI is the preferred modality for detecting brain metastases [31] . 18 F-FDG PET/CT could unveil metastases that otherwise escape detection (e.g., soft-tissue lesions, small supraclavicular lymph nodes, and retroperitoneal lymph nodes). Previous studies found that 18 F-FDG PET and PET/CT resulted in a staging change in 27-62 % of patients with NSCLC and altered patient management in 19-52 % [13, 14, 32, 33] . Hicks et al. showed that 18 F-FDG PET staging had a major impact on the treatment plan in 54 of 153 (35 %) patients with newly diagnosed NSCLC [32] . Treatment was changed from curative to palliative in 34 patients and from palliative to curative in 6. In 14 patients, the treatment modality was altered without a change in treatment intent. In summary, 18 F-FDG PET/ CT is a highly sensitive and specific modality for detecting distant metastases of lung cancer (excluding brain metastases).
Radiotherapy planning
Radiotherapy is the treatment of choice for curative intent in patients with early-stage (stage I-II) NSCLC who are show abnormal FDG uptake corresponding to local recurrence at the postoperative stump (arrow). It is difficult to diagnose this local recurrence by CT alone. d 18 F-FDG PET/CT and e CT show abnormal FDG uptakes corresponding to the right pleural dissemination (arrows). It is difficult to diagnose pleural dissemination by CT alone. f 18 F-FDG PET/CT shows abnormal FDG uptakes corresponding to liver metastases (arrows) and pedicle bony metastasis (curved arrow). It is difficult to diagnose this bone metastasis based on CT alone 1 3 contraindicated for surgery. The majority of 18 F-FDG PET studies are performed for preoperative staging; however, the metabolic information provided by the procedure may facilitate radiotherapy planning. Accurate identification of locoregional tumor load could determine the type of therapeutic intervention, the tumor volume targeted by radiotherapy, and (consequently) the toxicity. For classical radiotherapy planning, CT is used to delineate the target tumor volume. Disadvantages associated with CT include poor delineation of some tumors because of accompanying atelectasis and limited accuracy for detecting lymphatic involvement. With its improved accuracy, 18 F-FDG PET/ CT-based radiotherapy planning could improve delineation and avoid unnecessary irradiation to adjacent nontumoral tissues. Furthermore, in patients with NSCLC, 18 F-FDG PET could lead to significant treatment strategy modifications and radiotherapy planning alterations [34] . Studies concerning the impact of 18 F-FDG PET/CT on radiotherapy planning have demonstrated that the tumoral and nodal contours could be altered in >50 % of patients with probable improved tumoral coverage [35] . Additionally, 18 F-FDG PET/CT-derived tumor volumes were smaller compared to those derived by CT alone; this facilitates radiation dose escalation while respecting normal tissue constraints [36] . In a study of 21 patients with clinical CT stage N2-3 tumors, the gross tumor volume significantly decreased from 13.7 ± 3.8 cm 3 on the CT scan to 9.8 ± 4.0 cm 3 on the 18 F-FDG PET/CT scan. In another study, the incorporation of 18 F-FDG PET/CT data for radiotherapy planning significantly reduced the estimated doses to the esophagus and lungs [37] . Moreover, interobserver variability in delineating tumor volumes was diminished when 18 F-FDG PET was used for planning [38] . In addition to its enhanced clinical value in radiotherapy planning, the use of 18 F-FDG PET/CT altered the therapeutic strategy in 40 % of patients with NSCLC, which resulted in an overall cost reduction for treatment in this group [39] .
The use of respiratory gating in integrated 18 F-FDG PET/CT has been evaluated recently, especially its clinical impact on planning target volumes for radiation therapy. Preliminary results in patients with lung cancer showed that respiratory-gated 18 F-FDG PET/CT, which tailors the target volume to lesion motion, can affect the size and shape of target volumes, leading to improved delineation [40] .
Therapy response evaluation
In oncological settings, early assessment of therapeutic response enables treatment alteration in cases of nonresponse. Response assessment using conventional imaging depends mostly on changes in tumor volume. Therapyinduced tumor size reduction is measured by radiologic techniques, such as CT, according to the World Health Organization and the response evaluation criteria in solid tumors (RECIST). However, compared to conventional structural imaging modalities, evaluation of metabolic activity using 18 F-FDG PET provides valuable response information at an earlier time point [41] . In 73 NSCLC patients evaluated using 18 F-FDG PET and enhanced CT before and at a median interval of 70 days after radiotherapy and chemoradiotherapy, 18 F-FDG PET metabolic and CT morphologic response categories were identical in 40 % of patients, with significantly more patients (n = 34) showing a complete metabolic response (CMR) than showing a complete response on CT (n = 10) [42] . Furthermore, response assessment with morphologic imaging techniques has limitations in distinguishing necrotic tumors or fibrotic scars from residual tumor tissue. From this point of view, PET can be used to characterize tissues based on their biochemical and biological features (Fig. 5) [41] .
Response evaluation using 18 F-FDG PET in patients who underwent chemotherapy or chemoradiotherapy has been evaluated extensively [43] [44] [45] [46] . Studies comparing 18 F-FDG PET and non-enhanced CT suggested that 18 F-FDG PET was a better predictor of response [47] . Changes in tumor metabolic activity on 18 F-FDG PET scans were significantly greater in histologically confirmed chemotherapy responders compared to nonresponders [43] . Furthermore, the change in SUVmax after chemotherapy/ chemoradiotherapy showed a near-linear relationship with the percentage of nonviable tumor cells in the resected tumors [44] . The outcomes of patients who demonstrated a CMR were superior to those of the patients who did not [41] [42] [43] [44] [45] [46] .
The utility of 18 F-FDG PET for therapy response assessment and outcome prediction after neoadjuvant radiochemotherapy was evaluated in 70 patients with stage III NSCLC [45] . That study demonstrated that the sensitivity, specificity, and accuracy of FDG-PET to detect residual viable primary tumor were 95, 80, and 91 %, respectively. Additionally, patients with a CMR (as determined by qualitative criteria) or an 80 % reduction in the SUVmax had significantly longer survival compared to those with a partial metabolic response (PMR). Progressive disease on 18 F-FDG PET was significantly associated with an unfavorable outcome. Similarly, Mac Manus et al. [42] demonstrated that patients showing a CMR survived longer than those showing a PMR; in turn, survival in the latter group was superior to that of nonresponders (stable or progressive metabolic disease). By contrast, a recent study involving 89 patients from two consecutive phase II clinical trials of chemotherapy for NSCLC found that the response on 18 F-FDG PET did not predict outcome, whereas RECIST responses were associated with overall survival (OS) [47] .
Total lesion glycolysis (TLG) is calculated as the product of metabolic tumor volume (MTV) and the mean SUV of all voxels. MTV is defined as the volume of the delineated tumor on PET. In patients with locally advanced NSCLC treated with concomitant chemoradiotherapy, TLG has emerged as a predictor of progression-free survival (PFS) [48] and OS [49] . Yossi et al. [49] showed that a TLG decrease of >15 % after 30 Gy (up to a total dose of 66-70 Gy in 2-Gy fractions) was associated with improved OS and PFS.
One advantage of 18 F-FDG PET is the early detection of biological changes caused by decreased glucose metabolism in nonvital tissue, which facilitates earlier detection of responders and nonresponders as measured by 18 F-FDG retention [41, 50] . A significant reduction of 18 F-FDG uptake after one chemotherapy cycle was noted with various therapeutic regimens, and changes in uptake correlated with both response according to RECIST1.1 and survival [51] [52] [53] . Treatment can be adjusted on an individual basis according to tumor chemosensitivity as assessed by 18 F-FDG PET. Measurement methods of 18 F-FDG uptake are diverse, and timing with respect to anticancer therapy and thresholds used to define responses are variable. Therefore, further studies are required before definite conclusions can be drawn on using 18 F-FDG PET as a tool for therapy response monitoring.
In addition to its role in response evaluation of neoadjuvant chemotherapy in NSCLC, 18 F-FDG PET/CT has shown promise in monitoring response to biological agents such as epidermal growth factor receptor tyrosine kinase inhibitors (Fig. 5 ) [54] [55] [56] [57] . A review of 18 F-FDG PET/ CT use in targeted treatment for NSCLC suggested that response monitoring could be performed 1-2 weeks after treatment initiation, and that tumors showing a substantial decrease in metabolic activity would probably benefit from continued treatment. Refining FDG-PET response criteria might assist in clinical decision-making on the continuation or discontinuation of targeted treatment [57] .
In summary, 18 F-FDG PET/CT is emerging as a promising tool for early monitoring of the effectiveness of chemotherapy or chemoradiotherapy in lung cancer. However, there are substantial disparities with respect to response assessment, so standardization remains a requirement.
Monitoring of recurrence (restaging)
NSCLC has a high recurrence rate, even in patients treated with curative intent. Therefore, a method of selecting patients who have an increased risk of recurrence for further adjuvant therapy would be highly beneficial. Imaging plays a central role in recurrence detection, but chest radiograph and CT scan interpretation can be challenging because of posttreatment anatomical changes such as bronchi distortion, lung parenchyma infiltration, and fibrosis. In these settings, 18 F-FDG PET/CT is a powerful adjunct for patient follow-up after therapy (Fig. 4) . After radiotherapy, local tumor recurrence usually occurs within 2 years, but may create a diagnostic challenge because of the presence of mass-like radiation-induced fibrosis [58] . 18 F-FDG PET can distinguish recurrent tumors from fibrosis, providing that sufficient time (i.e., 3 months) has elapsed since treatment to eliminate the risk of false positivity associated with inflammatory changes [59] . In 62 NSCLC patients with suspected postsurgical recurrence, 18 F-FDG PET had a sensitivity and specificity of 93 and 89 %, respectively, for relapse detection [60] .
Distant metastases are the most prevalent form of NSCLC recurrence. Several groups have demonstrated the usefulness of NSCLC restaging using 18 F-FDG PET/CT (Fig. 4) [61, 62] . 18 F-FDG PET/CT showed high diagnostic performance for recurrence detection in 241 consecutive patients who underwent potentially curative surgery for NSCLC [61] . Because of the high NPV for recurrence detection, it was proposed that further conventional imaging (except for brain MRI) could be omitted in cases where 18 F-FDG PET/CT did not detect recurrence. In a recent meta-analysis that included 13 studies (1035 patients in total) on lung cancer recurrence, the pooled sensitivity and specificity were 0.90 (95 % CI, 0.84-0.95) and 0.90 (0.87-0.93), respectively, for 18 F-FDG PET/CT; and 0.78 (0.71-0.84) and 0.80 (0.75-0.84), respectively, for conventional imaging techniques [62] . Despite extensive studies showing excellent results for NSCLC restaging using 18 F-FDG PET/CT, the most recent American College of Chest Physicians evidence-based guidelines do not recommend 18 F-FDG PET/CT for routine surveillance after curative-intent treatment [63] .
Prognostication
Primary lesion metabolic activity is associated with indicators of aggressive biologic behavior such as the tumor doubling time and degree of differentiation [64] . Therefore, 18 F-FDG PET metabolic information might provide additional prognostic information based on the biological behavior of the tumor. Although most studies have reported that a high SUVmax was associated with a poorer prognosis [65] [66] [67] [68] [69] , others found that it was not an independent predictor for OS [70, 71] . In a study of 162 consecutive patients with stage I-IIIb NSCLC, the presence of low tumoral SUVmax was associated with increased 2-year disease-free survival rates for both early (I-II) and late (IIIa-IIIb) stage patients [65] . In a study that included 487 patients, SUVmax was an independent prognostic determinant along with the TNM stage, but it did not contribute to the prognostic value of pathologic staging [67] . A recent meta-analysis (1805 patients in total) including 18 studies demonstrated that both pre-radiotherapy and postradiotherapy primary tumor SUVmax could predict the outcomes of patients with NSCLC who underwent radiotherapy [68] .
In contrast, Agarwal et al. studied 363 patients with stage I and II NSCLC and demonstrated that the preoperative SUVmax was not an independent prognosticator for OS [70] . Similar results were noted in a retrospective analysis of 214 patients with stage IIIA, IIIB, and IV NSCLC [71] . SUVmax is not recommended for risk stratification in the 7th edition of the American Joint Committee on Cancer staging manual [3] , and is not considered a prognostic biomarker in the National Comprehensive Cancer Network guidelines (version 3, 2014) [72] .
Recent studies suggest that, compared to SUVmax, metabolic indices such as MTV and TLG might have better prognostic implications related to whole-body and primary tumor burdens [73] [74] [75] [76] [77] [78] . A recent meta-analysis (1581 patients in total) including 13 studies demonstrated that patients with a high MTV had worse prognosis for adverse events [hazard ratio (HR), 2.71; 95 % CI, 1.82-4.02] and death (HR, 2.31; 95 % CI, 1.54-3.47) compared to those with a low MTV [78] . Additionally, patients with a high TLG had worse prognosis with respect to adverse events (HR, 2.35; 95 % CI, 1.91-2.89) and death (HR, 2.43; 95 % CI, 1.89-3.11) [78] .
In addition to its prognostic value in pre-treatment evaluation, a recent prospective trial in patients with stage III NSCLC indicated that high tumor SUV after treatment was associated with poor prognosis [79] . A retrospective study of surveillance 18 F-FDG PET/CT during followup >6 months after treatment showed that 18 F-FDG PET was a prognosticator of OS [80] . Patients without recurrence according to 18 F-FDG PET/CT had a median survival time (MST) of 81.6 months compared with an MST of 32.9 months in those with suspected recurrence. Zhang et al. demonstrated that postsurgical whole-body metabolic tumor burden and tumor SUVmax were related to OS in patients with NSCLC, independent of age, sex, TNM restaging, and postsurgical therapy [81] .
In summary, 18 F-FDG PET/CT, including SUVmax, MTV, and TLG, might have prognostic value in patients with lung cancer, but further clarification studies are warranted.
SCLC
SCLC accounts for 15 % of lung cancers and is characterized by a rapid doubling time and aggressive clinical behavior, with a high prevalence of disseminated disease at diagnosis [2] . Although TNM staging is applied occasionally, the simplified dichotomous classification method of limited stage (LS) and extensive stage (ES) is used for SCLC staging. The standard therapies are concurrent chemoradiotherapy for patients with good performance status and LS disease, and palliative chemotherapy for those with ES disease. Despite initial chemosensitivity, overall prognosis is poor due to relapses. Given the difference in treatment strategies, accurate staging of SCLC is crucial. However, data concerning the use of 18 F-FDG PET/CT for SCLC staging [25, 28, 29, [82] [83] [84] [85] [86] [87] , radiotherapy planning [82, 83] , therapy response evaluation [88] [89] [90] , and prognosis [89] [90] [91] [92] [93] [94] are limited.
In a recent meta-analysis encompassing 12 papers and 369 patients, the pooled sensitivity and specificity of 18 F-FDG PET or PET/CT for the detection of extensive disease in SCLC were 0.98 (95 % CI 0.94-0.99) and 0.98 (95 % CI 0.95-0.99) [86] . The impact of 18 F-FDG PET on stage classification of newly diagnosed SCLC has been investigated in several studies which suggested that 18 F-FDG PET facilitated modifications of stage and clinical management in 12-26 % of cases [82] [83] [84] [85] [86] . Studies indicated that the incorporation of 18 F-FDG PET/CT data during initial staging led to changes in radiation fields in 37 % of patients [82] . High mean SUVmax values in pretreatment 18 F-FDG PET/CT scans were associated with poorer OS and PFS in both LS and ES SCLC patients [91] . Whole-body MTV of 18 F-FDG was of prognostic value in SCLC, and incorporation of metabolic data during TNM staging has been proposed to improve prognostic information [92] . Moreover, changes in MTV after radiotherapy correlated with survival in patients with LS SCLC [93] .
Conclusion
18 F-FDG PET/CT permits the combined metabolic and morphological assessment of tumors, with significant improvements in diagnostic accuracy and considerable impact on patient management, initial staging, therapy planning, early treatment response assessment, re-staging, and prognostication of lung cancer.
Further analyses to refine 18 F-FDG PET/CT response criteria, the standardization of 18 F-FDG PET/CT timing for chemotherapy or chemoradiotherapy response evaluation, the development of new PET cameras with higher spatial resolution, and the design of new radiotracers other than 18 F-FDG are required.
